Toll Free: 1-888-928-9744
Published: Jul, 2014 | Pages:
32 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Ganymed Pharmaceuticals AG - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'Ganymed Pharmaceuticals AG - Product Pipeline Review - 2014', provides an overview of the Ganymed Pharmaceuticals AG's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Ganymed Pharmaceuticals AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of Ganymed Pharmaceuticals AG including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Ganymed Pharmaceuticals AG's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the Ganymed Pharmaceuticals AG's pipeline products Reasons to buy - Evaluate Ganymed Pharmaceuticals AG's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Ganymed Pharmaceuticals AG in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Ganymed Pharmaceuticals AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Ganymed Pharmaceuticals AG and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ganymed Pharmaceuticals AG - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of Ganymed Pharmaceuticals AG and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Ganymed Pharmaceuticals AG Snapshot 5 Ganymed Pharmaceuticals AG Overview 5 Key Information 5 Key Facts 5 Ganymed Pharmaceuticals AG - Research and Development Overview 6 Key Therapeutic Areas 6 Ganymed Pharmaceuticals AG - Pipeline Review 9 Pipeline Products by Stage of Development 9 Pipeline Products - Monotherapy 10 Ganymed Pharmaceuticals AG - Pipeline Products Glance 11 Ganymed Pharmaceuticals AG - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 Ganymed Pharmaceuticals AG - Early Stage Pipeline Products 13 Discovery Products/Combination Treatment Modalities 13 Ganymed Pharmaceuticals AG - Drug Profiles 14 IMAB-362 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 IMAB-027 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Bispecific Monoclonal Antibodies to Inhibit CLDN6 for Solid Tumor 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 Conjugated Monoclonal Antibodies to Inhibit CDLN18.2 for Solid Tumors 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Conjugated Monoclonal Antibodies to Inhibit CLDN6 for Solid Tumors 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Monoclonal Antibodies to Inhibit CDLN18.2 for Solid Tumors 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Monoclonal Antibodies to Inhibit GT-468 for Oncology 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 Monoclonal Antibodies to Target GT-352 for Solid Tumors 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 Monoclonal Antibodies to Target GT-353 for Solid Tumors 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 Ganymed Pharmaceuticals AG - Pipeline Analysis 24 Ganymed Pharmaceuticals AG - Pipeline Products by Target 24 Ganymed Pharmaceuticals AG - Pipeline Products by Route of Administration 25 Ganymed Pharmaceuticals AG - Pipeline Products by Molecule Type 26 Ganymed Pharmaceuticals AG - Pipeline Products by Mechanism of Action 27 Ganymed Pharmaceuticals AG - Recent Pipeline Updates 28 Ganymed Pharmaceuticals AG - Locations And Subsidiaries 30 Head Office 30 Appendix 31 Methodology 31 Coverage 31 Secondary Research 31 Primary Research 31 Expert Panel Validation 31 Contact Us 32 Disclaimer 32
List of Tables Ganymed Pharmaceuticals AG, Key Information 5 Ganymed Pharmaceuticals AG, Key Facts 5 Ganymed Pharmaceuticals AG - Pipeline by Indication, 2014 8 Ganymed Pharmaceuticals AG - Pipeline by Stage of Development, 2014 9 Ganymed Pharmaceuticals AG - Monotherapy Products in Pipeline, 2014 10 Ganymed Pharmaceuticals AG - Phase II, 2014 11 Ganymed Pharmaceuticals AG - Phase I, 2014 12 Ganymed Pharmaceuticals AG - Discovery, 2014 13 Ganymed Pharmaceuticals AG - Pipeline by Target, 2014 24 Ganymed Pharmaceuticals AG - Pipeline by Route of Administration, 2014 25 Ganymed Pharmaceuticals AG - Pipeline by Molecule Type, 2014 26 Ganymed Pharmaceuticals AG - Pipeline Products by Mechanism of Action, 2014 27 Ganymed Pharmaceuticals AG - Recent Pipeline Updates, 2014 28
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.